Top NYC, NY Health Tech Companies With Best Stability & Growth (853)

Investor Backing & Capital Strength: Successive up-rounds (Series C in 2023 and Series D in 2024) with a marked valuation step-up indicate strong investor conviction and ample capital for expansion. Feedback suggests this funding underpins continued product investment and nationwide scaling.

Market Expansion: The platform reports activity in all 50 states and D.C., rising provider and patient counts, and expansion into Medicare Advantage and Medicaid. Help-center updates and company materials highlight broader coverage and multi‑state credentialing enabling nationwide reach.

Strategic Partnerships: Participation with major insurers (e.g., Aetna, select BCBS plans, Cigna/Evernorth, UnitedHealthcare/Optum) and support from partners like BCBS Massachusetts signal strong payer alignment. These relationships appear to facilitate national scale and access across plan types.

Investor Backing & Capital Strength: Recent Series C (March 2025) from Dassault Systèmes/Medidata and a $50M Series D (April 2026) funded by Boehringer Ingelheim demonstrate continued access to capital aligned with commercialization plans. Long-standing pharma ties with Otsuka and Boehringer, including sizable milestone frameworks, further reinforce capital strength.

Product Line Growth: Two FDA-authorized products (Rejoyn for MDD; CT-132 for migraine) and a Phase 3–positive schizophrenia PDT (CT-155) expand the portfolio from R&D into early commercialization. Acquisitions and new offerings (Better Therapeutics’ AspyreRx IP and the Click SE initiative) broaden therapeutic scope.

Strategic Partnerships: Enduring alliances with Otsuka and Boehringer, plus a strategic integration investment from Dassault Systèmes/Medidata, indicate strong external validation and go-to-market support. Category-shaping moves like Click SE (aligned with FDA PDURS) aim to deepen co-labeling and pharma collaboration opportunities.

Profitability: The company reports achieving annual profitability in 2023 and sustaining it, with a 2025 Rule‑of‑40 score of 51% indicating efficiency in combining growth and margin. These signals point to durable unit economics rather than growth fueled by losses.

Strong Revenue Growth: Leadership cites roughly a 30% revenue CAGR over the past three years with acceleration into 2026. Continued national marketing and expanded booking channels align with ongoing top‑line momentum.

Strategic Partnerships: New integrations—such as Blue Shield of California’s member scheduling and Yelp’s real‑time booking—extend distribution beyond the core marketplace. These moves position the platform as access infrastructure across payer and high‑intent consumer surfaces.

Investor Backing & Capital Strength: Funding progressed from a Series A to a Series B and a Series C led by well-known investors, with mainstream and trade press coverage indicating strong capital access and runway.

Strategic Partnerships: Broad integrations with leading senior‑living EHRs and a named Client Advisory Board from recognized operators indicate deep ecosystem alignment and industry engagement.

Market Expansion: Portfolio‑level rollouts and added integrations that open access across much of the senior‑living ecosystem suggest an expanding commercial footprint.

Strategic Partnerships: Recent distribution via a benefits platform (StretchDollar) places the service inside employer channels, signaling expanded go‑to‑market reach. Public partner materials indicate the advocacy service is being offered as an employer perk, broadening access beyond direct-to-consumer.

Investor Backing & Capital Strength: A 2024 Form D filing under the prior legal name and references to a significant seed raise indicate fresh capital to support scaling. The filing signed by the CEO points to formal fundraising intended to fuel growth initiatives.

Market Expansion: Company materials now market consumer outcomes and claim broad family trust, suggesting increased reach since the rebrand. Coverage in a major newspaper feature on using chatbots to fight medical bills elevated visibility in the core problem space.

Product Line Growth: Evidence indicates non‑COVID brands and newly launched/acquired assets are expanding, with growth led by Eliquis, Vyndaqel/Vyndamax, oncology biosimilars, Nurtec, and Seagen‑originated therapies such as Padcev.

Future-Ready Strategy: Company materials highlight the Seagen acquisition as a multi‑year oncology growth engine alongside recent approvals and advancing vaccine programs, with numerous pivotal starts planned to add future contributors.

Cost & Operational Efficiency: Disclosures describe a multi‑year cost realignment targeting substantial net savings, alongside deleveraging priorities and expected integration synergies to support margin stability during the revenue mix shift.

Product Line Growth: Product launches such as expanded Cedar Intelligence for billing, the Kora AI voice agent, and affordability tools indicate a steady cadence of feature expansion. These additions broaden use cases from post‑visit billing into coverage, affordability, and automated support.

Market Expansion: New deployments and marketplace integrations (e.g., health‑system wins, ambulatory channels, and marketplace distribution) show expanding reach across health systems, medical groups, and practices. Such channels open growth vectors beyond large enterprise hospital deals.

Strategic Partnerships: Partnerships and ecosystem collaborations (e.g., marketplace integrations and communications platforms) support scale and adoption. An acquisition expanding payer–provider workflows further extends platform breadth and go‑to‑market leverage.

Market Expansion: Public claims and profiles trace clinic adoption from a 2019 baseline to “over 23,000” hospitals/clinics by 2024–2026, indicating sustained footprint growth. Additional signals such as active manufacturer program pages and continued rollouts for groups suggest deeper reach across segments.

Product Line Growth: The platform has expanded beyond procurement into Home Delivery pharmacy and added integrations with major practice‑management systems, embedding it further into daily workflows. Ongoing feature launches for groups and hospitals are cited as leading indicators of broader adoption.

Strategic Partnerships: Company and partner pages reference collaborations like AVMA Direct Connect and active manufacturer programs (e.g., Dechra), signaling vendor‑side engagement. Ecosystem integrations and partner endorsements depict a well‑connected position in the animal health supply chain.

Market Expansion: Public materials indicate the network has expanded to 6,000+ research sites across 50+ countries and 25+ sponsors, up from 5,500+ sites cited in late 2025. This footprint growth signals broader geographic reach and increasing demand-side participation.

Strategic Partnerships: Announced partnerships such as the September 2025 RealTime eClinical data-integration open access to 50+ large site networks (2,000+ sites) and enrich marketplace data. Additional integrations (e.g., eClinPro in 2026) reinforce distribution and embed the platform more deeply in site workflows.

Innovation-Driven Growth: The company launched AI-enabled pre-screening, AI site selection, and EHR integration in 2025–2026 to improve patient identification and sponsor decision-making. These capabilities can increase conversion and make the platform more attractive to both sites and sponsors.

Investor Backing & Capital Strength: Recent financing rounds, including a sizable Series B and an additional credit facility, indicate strong investor confidence and ample runway. The capital is explicitly tied to hiring, go‑to‑market, and product expansion plans across 2024–2026 communications.

Product Line Growth: Ongoing launches such as AI‑powered Claims Analytics and “Zoe for HR” suggest continued investment in expanding the platform. Added capabilities like a cash‑pay network and pharmacy‑related tools point to a broadened offering beyond core navigation.

Strategic Partnerships: Partnerships with platforms and channels such as TriNet, Workday Wellness, PrismHR, and benefit alliances indicate growing distribution reach. Event participation and partner documentation suggest active customer acquisition across employer and PEO ecosystems.

Strong Revenue Growth: Independent private‑market researchers indicate annualized revenue rose meaningfully in 2024, showing a clear upturn driven by GLP‑1 obesity care. This reacceleration suggests business momentum returned after earlier slowdowns.

Strategic Partnerships: In April 2025, Novo Nordisk chose Ro to sell Wegovy at a lower cash price via Novo’s pharmacy channel, likely funneling incremental demand to the platform. Ongoing promotions and subscription‑style pricing through this channel indicate continued partner alignment.

Product Line Growth: Ro launched and scaled a GLP‑1 weight‑management program and published weight‑loss and lab‑improvement results supporting ongoing use and cross‑sell within its telehealth and pharmacy stack. Integration with manufacturer channels further enhanced program reach and conversion.

Strong Revenue Growth: Full‑year 2025 total revenue rose 23% to $255.9M with software up 11%, highlighting broader adoption and upsell including more hosted deployments. ACV reached $201M on a trailing four‑quarter basis and grew 12% in Q1 2026, with 2026 ACV guided to 10–15% growth.

Strategic Partnerships: Progress in collaborations and co‑founded or partnered programs lifted drug‑discovery revenue (Q1 2026 more than doubled, and 2026 guidance is $55–$65M). The company is pursuing partnerships for oncology assets SGR‑1505 and SGR‑3515 and highlighted potential milestone and liquidity events.

Future-Ready Strategy: Management is transitioning software from term licenses to hosted subscriptions and outlined 2026 priorities to scale the “physics+AI” platform and release the Bunsen agentic AI “co‑scientist.” Feedback suggests this shift should aid scalability and retention even as near‑term revenue recognition is choppy.

Investor Backing & Capital Strength: Funding announcements show Marble Health raised a $15.5M Series A in October 2025 led by Costanoa with participation from Town Hall Ventures and Khosla Ventures, signaling strong investor support. Company and investor communications indicate this capital is earmarked to scale operations, expand partnerships, and grow the team.

Market Expansion: Company updates indicate launches beyond New York into states like Ohio and New Jersey, pointing to a widening geographic footprint. Public materials also highlight school partnerships and rising therapy-session volumes since launch, consistent with expansion.

Strong Hiring & Retention: Open roles across growth, operations, and product on company and third‑party job boards indicate active team growth. Leadership posts describe go‑to‑market hiring momentum ahead of school years, suggesting sustained scaling efforts.

Investor Backing & Capital Strength: Company announcements highlight a $25M Series B at a significant valuation step-up with reputable investors participating. This indicates strong access to growth capital to fund scaling efforts.

Market Expansion: Company materials cite 10,000+ agents using the platform and roughly 225,000–250,000 enrollments in 2025, alongside notable gains at partner agencies. Active hiring and increases in RTS agent counts further signal expanding commercial reach.

Innovation-Driven Growth: Spark positions itself as an all-in-one, Medicare-specific platform with in-house software, AI features, and operational tooling for agencies and call centers. Leadership additions (CTO and COO) point to continued product and operating-model build-out.

Investor Backing & Capital Strength: Feedback suggests Inspiren closed sizable Series A and Series B rounds in 2025, signaling investor confidence and providing resources to scale.

Market Expansion: Feedback suggests company materials and trade coverage describe nationwide, multi‑site deployments with named operators, indicating an expanding footprint.

Product Line Growth: Feedback suggests 2025 launches of an integrated emergency call capability and the Inspiren Intelligence analytics layer broadened the platform to support further expansion.

Strong Hiring & Retention: Active hiring signals are evident with multiple recent postings across Operations, Engineering, Product, RCM, and Partnerships and a visible “We’re Hiring!” banner. Feedback suggests team size and social followership on LinkedIn are consistent with recent headcount expansion.

Market Expansion: The company markets Medicare-covered virtual psychotherapy “across all 50 states,” indicating a national footprint rather than a limited pilot. Self-described service to “thousands of patients” across many states further reinforces expanding reach.

Innovation-Driven Growth: The organization emphasizes an AI-native platform with real-time clinical insights and clinical copilots to scale care delivery and efficiency. This technology-forward posture supports growth in virtual operations for older adults.

Strong Revenue Growth: Repeated Inc. 5000 inclusion across 2021–2025 indicates multi‑year revenue expansion, with Inc. citing an 83% three‑year growth rate for the 2025 list. These external markers collectively point to sustained top‑line momentum.

Innovation-Driven Growth: AI‑driven launches in 2026 (RethinkBH AI Dashboard and Session Note AI) demonstrate ongoing product investment intended to enhance capability and adoption. Product momentum aligns with a growth posture centered on technology advancement.

Market Expansion: The August 2025 acquisition of Joshin expands the company’s neurodiversity and disability support offering, consistent with investing for growth. Scale indicators on the official site (e.g., Fortune 100 penetration and millions of lives served) further reflect broadening market reach.

Investor Backing & Capital Strength: GV led a $28.1M round in February 2023 to scale firsthand’s Medicaid-focused SMI model and multi‑state operations. This capital provides runway supporting ongoing activity despite subsequent turbulence.

Market Expansion: Operations span multiple states (e.g., Florida, Ohio, Michigan, Virginia, Washington) with active postings in 2026, indicating selective growth and continuation in targeted markets. Company materials and social updates point to stabilization and focused re‑entry after 2025 cuts.

Strategic Partnerships: The model centers on payer partnerships in Medicaid, and firsthand is a contracted provider with Molina, aligning offerings with managed‑care needs. Such plan relationships underpin access to attributed lives and contract‑driven revenue.

Investor Backing & Capital Strength: Recent Series B and Series C rounds total significant capital, signaling strong investor confidence and providing resources to scale. The company earmarks this funding to expand its clinical network, AI initiatives, and partnerships.

Strong Revenue Growth: Consistent revenue expansion since launch is highlighted by nine‑figure revenue in 2024 and statements of rapid year‑over‑year growth. Reports also note the company reached profitability in 2025 alongside continued scaling.

Strategic Partnerships: Partnerships with hundreds of health plans, employers, and health systems expand distribution and indicate payer/provider acceptance. Named collaborations (e.g., a health‑system integration) and nationwide in‑network availability broaden access and patient reach.

Strong Market Position & Advantage: Public materials indicate a nationwide footprint across roughly 30,000 physicians’ offices serving about 125,000 providers, with expanded MRC accreditation across waiting, exam and back‑office screens signaling a measurable, scaled network. These indicators suggest durable competitive positioning at the point of care.

Product Line Growth: In March 2026 the company launched a Consumer Health Network and added programmatic access via PatientPoint Health Audiences. These offerings expand monetization routes and modernize buying options for brands.

Investor Backing & Capital Strength: Advent International signed a definitive agreement to acquire the company to accelerate network growth and product innovation. Earlier private capital injections and active partnerships further suggest access to resources to fund expansion.